KRAS insertion mutations are oncogenic and exhibit distinct functional properties.

Area of Science:

• Molecular Biology
• Oncology
• Genetics

Background:

• Oncogenic KRAS mutations typically involve single amino acid substitutions that alter Ras GTPase activity and GAP interactions.
• Understanding novel KRAS alterations is crucial for cancer diagnostics and therapeutics.

Purpose of the Study:

• To identify and characterize a novel class of oncogenic KRAS mutations involving partial duplications in the switch 2 domain.
• To investigate the functional consequences of these mutations on K-Ras protein activity, signaling pathways, and cellular transformation.

Main Methods:

• Identification of a G60_A66dup K-Ras mutation in a patient with atypical myeloproliferative neoplasm.
• Characterization of recombinant K-Ras proteins with switch 2 tandem duplications (G60_A66dup and E62_A66dup).
• Assessment of GTPase activity, GAP resistance, cellular transformation, and pathway activation (PI3K/Akt, MEK).

Main Results:

• K-Ras switch 2 tandem duplications (G60_A66dup, E62_A66dup) confer oncogenic properties, transforming myeloid progenitors and Ba/F3 cells.
• Mutant K-Ras proteins exhibit reduced GTP hydrolysis, accumulate in the GTP-bound state, and resist GAP-mediated inactivation.
• These mutations impair PI3 kinase binding and Akt activation but lead to hypersensitivity to MEK inhibition.

Conclusions:

• A novel class of oncogenic KRAS mutations with switch 2 domain duplications has been identified.
• These mutations demonstrate plasticity in oncogenic Ras proteins, impacting distinct signaling pathways.
• These findings have significant diagnostic implications and suggest targeted therapeutic strategies, particularly MEK inhibition.